The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1481
Budesonide Rectal Foam (Uceris) for Ulcerative Colitis
The full article is available to subscribers Subscriber Login   

The FDA has approved a rectal foam formulation of the corticosteroid budesonide (Uceris - Salix/Valeant) for induction of remission in patients with active mild to moderate distal ulcerative colitis (UC) extending up to 40 cm from the anal verge. Budesonide is also available as oral extended-release tablets (also branded as Uceris) for use in patients with UC and as oral enteric-coated tablets (Entocort EC, and generics) for treatment of Crohn's disease.1,2

TOPICAL TREATMENT OF DISTAL UC – Rectally instilled aminosalicylates and corticosteroids can induce remission in mild to moderate distal UC. Enemas reach the splenic flexure, but may be difficult for patients to tolerate. Hydrocortisone rectal foam (Cortifoam) and mesalamine rectal suppositories (Canasa) are better tolerated, but their activity is generally limited to the 15 cm and ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Budesonide Rectal Foam (Uceris) for Ulcerative Colitis
Article code: 1481c
 Electronic, downloadable article - $35
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian